Jeetinder Singh Mahal
Known title: See RemarksCIK: 0001882877
Associated companies
Transaction History
| JSPR | ▲ Buy | Option Exercise | 900 | $6K | 12/12/2024 | View on chart |
| JSPR | ▼ Sell | Open Market | 900 | $20K | 12/12/2024 | View on chart |
| JSPR | ▼ Sell | Open Market | 900 | $19K | 9/12/2024 | View on chart |
| JSPR | ▲ Buy | Option Exercise | 900 | $6K | 9/12/2024 | View on chart |
| JSPR | ▲ Buy | Option Exercise | 900 | $6K | 6/12/2024 | View on chart |
| JSPR | ▼ Sell | Open Market | 900 | $22K | 6/12/2024 | View on chart |
| JSPR | ▲ Buy | Option Exercise | 900 | $6K | 3/12/2024 | View on chart |
| JSPR | ▼ Sell | Open Market | 900 | $24K | 3/12/2024 | View on chart |
| JSPR | ▼ Sell | Tax Withholding | 37,126 | $32K | 10/12/2023 | View on chart |
| JSPR | ▲ Buy | Option Exercise | 9,000 | $6K | 6/13/2023 | View on chart |
| JSPR | ▼ Sell | Open Market | 9,000 | $15K | 6/13/2023 | View on chart |
| JSPR | ▼ Sell | Tax Withholding | 37,126 | $54K | 4/12/2023 | View on chart |
| JSPR | ▲ Buy | Grant | 214,722 | $0 | 10/12/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Jasper Therapeutics Names Interim CFO
Jasper Therapeutics announced that Herb Cross will resign as Chief Financial Officer effective October 9, 2026. Jeet Mahal has been appointed as the interim Principal Financial Officer to take over the role. This leadership change occurs while the stock trades well below its 52-week high and near recent support levels.
Jasper Therapeutics Names Interim CFO. Jasper Therapeutics announced that Herb Cross will resign as Chief Financial Officer effective October 9, 2026. Jeet Mahal has been appointed as the interim Principal Financial Officer to take over the role. This leadership change occurs while the stock trades well below its 52-week high and near recent support levels.